Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00GEG
|
||||
| Former ID |
DCL000949
|
||||
| Drug Name |
Ralfinamide
|
||||
| Synonyms |
Ralfinamida; Ralfinamide [INN]; NW 1029; NW-1029; Ralfinamida [INN-Spanish]; (2S)-2-(4-(2-Fluorobenzyloxy)benzylamino)propanamide; (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Neuropathic pain [ICD9: 356.0, 356.8; ICD10:G64, G90.0] | Phase 3 | [536374] | ||
| Therapeutic Class |
Analgesics
|
||||
| Company |
Newron
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H19FN2O2
|
||||
| Canonical SMILES |
CC(C(=O)N)NCC1=CC=C(C=C1)OCC2=CC=CC=C2F
|
||||
| InChI |
1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-6-8-15(9-7-13)22-11-14-4-2-3-5-16(14)18/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
|
||||
| InChIKey |
BHJIBOFHEFDSAU-LBPRGKRZSA-N
|
||||
| CAS Number |
CAS 133865-88-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7980092, 11765991, 14849629, 16401816, 39540275, 80386629, 96099947, 114110606, 126665943, 127515934, 134339388, 135141179, 137040444, 141494069, 143315338, 160682207, 160834801, 162787156, 163400935, 163845541, 172860201, 179149836, 198939625, 204430313, 223628301, 223658050, 224284737, 225376533, 226448238, 252255024, 252494047
|
||||
| Target and Pathway | |||||
| Target(s) | Voltage-dependent N-type calcium channel | Target Info | Blocker | [536374] | |
| Sodium channel | Target Info | Blocker | [536374] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Calcium signaling pathway | |||||
| Synaptic vesicle cycle | |||||
| Retrograde endocannabinoid signaling | |||||
| Cholinergic synapse | |||||
| Serotonergic synapse | |||||
| GABAergic synapse | |||||
| Dopaminergic synapse | |||||
| Taste transduction | |||||
| Type II diabetes mellitus | |||||
| Morphine addiction | |||||
| Nicotine addictionhsa04728:Dopaminergic synapse | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Ionotropic glutamate receptor pathway | |||||
| Metabotropic glutamate receptor group III pathway | |||||
| Metabotropic glutamate receptor group II pathway | |||||
| Thyrotropin-releasing hormone receptor signaling pathway | |||||
| Endogenous cannabinoid signaling | |||||
| GABA-B receptor II signaling | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.